Trough-level guided dosing is reliable for mycophenolate mofetil but not for enteric-coated mycophenolic sodium

被引：0
|
作者：
Von Moos, Seraina [1 ]
Rho, Elena [2 ]
Lopez, Kai Castrezana [2 ]
Weidmann, Lukas [2 ]
George, Britta [2 ]
Pfister, Susan [2 ]
Schachtner, Thomas [2 ]
机构：
[1] Cantonal Hosp Luzern, Luzern, Switzerland
[2] Univ Hosp Zurich, Div Nephrol, Zurich, Switzerland
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2024年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
2047
引用
收藏
页码：I1632 / I1633
页数：2
相关论文
共 50 条
  • [21] Enteric-coated mycophenolate sodium: an update
    Zhang, W.
    Ding, C.
    Zheng, S.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2014, 68 : 1 - 3
  • [22] Sites of gastrointestinal lesion induced by mycophenolate mofetil: a comparison with enteric-coated mycophenolate sodium in rats
    Jia, Yichen
    Wang, Rulin
    Li, Long
    Zhang, Ying
    Li, Jiawei
    Wang, Jina
    Wang, Xuanchuan
    Qi, Guisheng
    Rong, Ruiming
    Xu, Ming
    Zhu, Tongyu
    BMC PHARMACOLOGY & TOXICOLOGY, 2018, 19
  • [23] Bioavailability of Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium Is Differentially Affected by Pantoprazole in Healthy Volunteers
    Rupprecht, Korbinian
    Schmidt, Christoph
    Raspe, Anne
    Schweda, Frank
    Shipkova, Maria
    Fischer, Wolfgang
    Bucher, Michael
    Kees, Frieder
    Faerber, Lothar
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (10): : 1196 - 1201
  • [24] Is Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium Justifiable for Gastrointestinal Quality of Life?
    Kyle M. Gardiner
    Susan E. Tett
    Christine E. Staatz
    Drugs in R&D, 2018, 18 : 271 - 282
  • [25] Sites of gastrointestinal lesion induced by mycophenolate mofetil: a comparison with enteric-coated mycophenolate sodium in rats
    Yichen Jia
    Rulin Wang
    Long Li
    Ying Zhang
    Jiawei Li
    Jina Wang
    Xuanchuan Wang
    Guisheng Qi
    Ruiming Rong
    Ming Xu
    Tongyu Zhu
    BMC Pharmacology and Toxicology, 19
  • [26] Is Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium Justifiable for Gastrointestinal Quality of Life?
    Gardiner, Kyle M.
    Tett, Susan E.
    Staatz, Christine E.
    DRUGS IN R&D, 2018, 18 (04) : 271 - 282
  • [27] Renal transplant patients with gastrointestinal intolerability to mycophenolate mofetil: Conversion to enteric-coated mycophenolate sodium
    Calvo, N.
    Sanchez-Fructuoso, A. I.
    Conesa, J.
    Moreno, A.
    Barrientos, A.
    TRANSPLANTATION PROCEEDINGS, 2006, 38 (08) : 2396 - 2397
  • [28] Enteric-coated mycophenolate sodium immunosuppression in renal transplant patients: efficacy and dosing
    Cooper, Matthew
    Salvadori, Maurizio
    Budde, Klemens
    Oppenheimer, Frederic
    Sollinger, Hans
    Zeier, Martin
    TRANSPLANTATION REVIEWS, 2012, 26 (04) : 233 - 240
  • [29] Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric-coated mycophenolate versus mycophenolate mofetil in patients with progressive IgA nephritis
    Czock, David
    Rasche, Franz Maximilian
    Carius, Alexander
    Glander, Petra
    Budde, Klemens
    Bauer, Steffen
    Keller, Frieder
    von Mueller, Lutz
    JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (07): : 850 - 859
  • [30] Mycophenolate Mofetil Versus Enteric-Coated Mycophenolate Sodium After Simultaneous Pancreas-Kidney Transplantation
    Rangel, E. B.
    Melaragno, C. S.
    Sa, J. R.
    Gonzalez, A. M.
    Linhares, M. M.
    Salzedas, A.
    Medina-Pestana, J. O.
    TRANSPLANTATION PROCEEDINGS, 2009, 41 (10) : 4265 - 4269
12345